nodes	percent_of_prediction	percent_of_DWPC	metapath
Desipramine—CYP2A6—Methimazole—Graves' disease	0.225	0.276	CbGbCtD
Desipramine—CYP2E1—Methimazole—Graves' disease	0.149	0.182	CbGbCtD
Desipramine—CYP2B6—Methimazole—Graves' disease	0.147	0.18	CbGbCtD
Desipramine—CYP2C19—Methimazole—Graves' disease	0.0931	0.114	CbGbCtD
Desipramine—CYP1A2—Methimazole—Graves' disease	0.0859	0.105	CbGbCtD
Desipramine—CYP2D6—Methimazole—Graves' disease	0.0708	0.0869	CbGbCtD
Desipramine—CYP3A4—Methimazole—Graves' disease	0.045	0.0552	CbGbCtD
Desipramine—Drug fever—Methimazole—Graves' disease	0.022	0.13	CcSEcCtD
Desipramine—Epigastric distress—Methimazole—Graves' disease	0.0189	0.112	CcSEcCtD
Desipramine—Drug fever—Propylthiouracil—Graves' disease	0.0187	0.11	CcSEcCtD
Desipramine—Epigastric distress—Propylthiouracil—Graves' disease	0.0161	0.0949	CcSEcCtD
Desipramine—Drowsiness—Methimazole—Graves' disease	0.00411	0.0242	CcSEcCtD
Desipramine—Neuropathy peripheral—Methimazole—Graves' disease	0.00402	0.0237	CcSEcCtD
Desipramine—Jaundice—Methimazole—Graves' disease	0.004	0.0236	CcSEcCtD
Desipramine—Agranulocytosis—Methimazole—Graves' disease	0.00383	0.0226	CcSEcCtD
Desipramine—Hepatitis—Methimazole—Graves' disease	0.00369	0.0217	CcSEcCtD
Desipramine—Drowsiness—Propylthiouracil—Graves' disease	0.00349	0.0206	CcSEcCtD
Desipramine—Neuropathy peripheral—Propylthiouracil—Graves' disease	0.00342	0.0202	CcSEcCtD
Desipramine—Jaundice—Propylthiouracil—Graves' disease	0.0034	0.0201	CcSEcCtD
Desipramine—Agranulocytosis—Propylthiouracil—Graves' disease	0.00326	0.0192	CcSEcCtD
Desipramine—Alopecia—Methimazole—Graves' disease	0.00326	0.0192	CcSEcCtD
Desipramine—Hepatitis—Propylthiouracil—Graves' disease	0.00313	0.0185	CcSEcCtD
Desipramine—Alopecia—Propylthiouracil—Graves' disease	0.00277	0.0163	CcSEcCtD
Desipramine—Dysgeusia—Propylthiouracil—Graves' disease	0.00267	0.0158	CcSEcCtD
Desipramine—Oedema—Methimazole—Graves' disease	0.00262	0.0154	CcSEcCtD
Desipramine—Thrombocytopenia—Methimazole—Graves' disease	0.00256	0.0151	CcSEcCtD
Desipramine—Paraesthesia—Methimazole—Graves' disease	0.00235	0.0139	CcSEcCtD
Desipramine—Somnolence—Methimazole—Graves' disease	0.00233	0.0137	CcSEcCtD
Desipramine—Dyspepsia—Methimazole—Graves' disease	0.00231	0.0136	CcSEcCtD
Desipramine—Oedema—Propylthiouracil—Graves' disease	0.00223	0.0131	CcSEcCtD
Desipramine—Thrombocytopenia—Propylthiouracil—Graves' disease	0.00218	0.0129	CcSEcCtD
Desipramine—Urticaria—Methimazole—Graves' disease	0.00208	0.0123	CcSEcCtD
Desipramine—Body temperature increased—Methimazole—Graves' disease	0.00207	0.0122	CcSEcCtD
Desipramine—Paraesthesia—Propylthiouracil—Graves' disease	0.002	0.0118	CcSEcCtD
Desipramine—Somnolence—Propylthiouracil—Graves' disease	0.00198	0.0117	CcSEcCtD
Desipramine—Dyspepsia—Propylthiouracil—Graves' disease	0.00196	0.0116	CcSEcCtD
Desipramine—Pruritus—Methimazole—Graves' disease	0.00185	0.0109	CcSEcCtD
Desipramine—Urticaria—Propylthiouracil—Graves' disease	0.00177	0.0104	CcSEcCtD
Desipramine—Body temperature increased—Propylthiouracil—Graves' disease	0.00176	0.0104	CcSEcCtD
Desipramine—Vomiting—Methimazole—Graves' disease	0.00166	0.00982	CcSEcCtD
Desipramine—Rash—Methimazole—Graves' disease	0.00165	0.00974	CcSEcCtD
Desipramine—Dermatitis—Methimazole—Graves' disease	0.00165	0.00973	CcSEcCtD
Desipramine—Headache—Methimazole—Graves' disease	0.00164	0.00968	CcSEcCtD
Desipramine—Pruritus—Propylthiouracil—Graves' disease	0.00158	0.00929	CcSEcCtD
Desipramine—Nausea—Methimazole—Graves' disease	0.00156	0.00917	CcSEcCtD
Desipramine—Vomiting—Propylthiouracil—Graves' disease	0.00142	0.00835	CcSEcCtD
Desipramine—Rash—Propylthiouracil—Graves' disease	0.0014	0.00828	CcSEcCtD
Desipramine—Dermatitis—Propylthiouracil—Graves' disease	0.0014	0.00827	CcSEcCtD
Desipramine—Headache—Propylthiouracil—Graves' disease	0.00139	0.00823	CcSEcCtD
Desipramine—Nausea—Propylthiouracil—Graves' disease	0.00132	0.0078	CcSEcCtD
Desipramine—SMPD1—connective tissue—Graves' disease	0.00126	0.0945	CbGeAlD
Desipramine—SMPD1—adipose tissue—Graves' disease	0.000965	0.0725	CbGeAlD
Desipramine—CHRM5—eye—Graves' disease	0.000868	0.0653	CbGeAlD
Desipramine—SMPD1—thyroid gland—Graves' disease	0.000835	0.0628	CbGeAlD
Desipramine—ADRB1—connective tissue—Graves' disease	0.000543	0.0408	CbGeAlD
Desipramine—SLC22A3—connective tissue—Graves' disease	0.000539	0.0405	CbGeAlD
Desipramine—CYP2A6—adipose tissue—Graves' disease	0.000519	0.039	CbGeAlD
Desipramine—SLC22A4—pituitary gland—Graves' disease	0.000456	0.0343	CbGeAlD
Desipramine—SLC22A4—adipose tissue—Graves' disease	0.000454	0.0342	CbGeAlD
Desipramine—DRD2—eye—Graves' disease	0.000437	0.0328	CbGeAlD
Desipramine—SLC22A1—adipose tissue—Graves' disease	0.000433	0.0325	CbGeAlD
Desipramine—ADRB1—adipose tissue—Graves' disease	0.000417	0.0313	CbGeAlD
Desipramine—SLC22A3—adipose tissue—Graves' disease	0.000414	0.0311	CbGeAlD
Desipramine—SLC22A4—thyroid gland—Graves' disease	0.000393	0.0296	CbGeAlD
Desipramine—CHRM3—adipose tissue—Graves' disease	0.000359	0.027	CbGeAlD
Desipramine—SLC22A3—thyroid gland—Graves' disease	0.000358	0.0269	CbGeAlD
Desipramine—HRH1—eye—Graves' disease	0.000345	0.0259	CbGeAlD
Desipramine—HRH1—connective tissue—Graves' disease	0.000332	0.025	CbGeAlD
Desipramine—DRD2—pituitary gland—Graves' disease	0.000324	0.0244	CbGeAlD
Desipramine—CHRM3—thyroid gland—Graves' disease	0.000311	0.0233	CbGeAlD
Desipramine—SLC22A5—pituitary gland—Graves' disease	0.000302	0.0227	CbGeAlD
Desipramine—SLC22A5—adipose tissue—Graves' disease	0.000301	0.0226	CbGeAlD
Desipramine—HTR2A—eye—Graves' disease	0.000288	0.0217	CbGeAlD
Desipramine—HTR2A—connective tissue—Graves' disease	0.000278	0.0209	CbGeAlD
Desipramine—SLC22A5—thyroid gland—Graves' disease	0.00026	0.0196	CbGeAlD
Desipramine—HRH1—adipose tissue—Graves' disease	0.000255	0.0192	CbGeAlD
Desipramine—CYP1A2—thyroid gland—Graves' disease	0.000236	0.0177	CbGeAlD
Desipramine—HTR2A—pituitary gland—Graves' disease	0.000214	0.0161	CbGeAlD
Desipramine—CYP2E1—thyroid gland—Graves' disease	0.000212	0.0159	CbGeAlD
Desipramine—ABCB1—pituitary gland—Graves' disease	0.00014	0.0105	CbGeAlD
Desipramine—ABCB1—adipose tissue—Graves' disease	0.00014	0.0105	CbGeAlD
Desipramine—ABCB1—thyroid gland—Graves' disease	0.000121	0.00908	CbGeAlD
Desipramine—CHRM1—GPCRs, Class A Rhodopsin-like—GPR174—Graves' disease	4.09e-05	0.0185	CbGpPWpGaD
Desipramine—CHRM3—GPCRs, Class A Rhodopsin-like—GPR174—Graves' disease	4.08e-05	0.0185	CbGpPWpGaD
Desipramine—ADRB2—Arf6 trafficking events—TSHR—Graves' disease	4.04e-05	0.0183	CbGpPWpGaD
Desipramine—CHRM2—GPCRs, Class A Rhodopsin-like—GPR174—Graves' disease	4.04e-05	0.0183	CbGpPWpGaD
Desipramine—SMPD1—Metabolism of lipids and lipoproteins—GC—Graves' disease	3.14e-05	0.0142	CbGpPWpGaD
Desipramine—SMPD1—TNF receptor signaling pathway —TNF—Graves' disease	3.11e-05	0.0141	CbGpPWpGaD
Desipramine—SMPD1—Ceramide signaling pathway—TNF—Graves' disease	3e-05	0.0136	CbGpPWpGaD
Desipramine—SLC6A4—Monoamine Transport—IL1B—Graves' disease	2.24e-05	0.0102	CbGpPWpGaD
Desipramine—SLC6A3—Transmission across Chemical Synapses—GABRA3—Graves' disease	2.01e-05	0.0091	CbGpPWpGaD
Desipramine—SLC6A2—Monoamine Transport—IL1B—Graves' disease	1.93e-05	0.00874	CbGpPWpGaD
Desipramine—ADRB1—G alpha (s) signalling events—TSHR—Graves' disease	1.9e-05	0.00862	CbGpPWpGaD
Desipramine—ADRB2—G alpha (s) signalling events—TSHR—Graves' disease	1.86e-05	0.00843	CbGpPWpGaD
Desipramine—SLC22A2—Transmission across Chemical Synapses—GABRA3—Graves' disease	1.83e-05	0.00828	CbGpPWpGaD
Desipramine—SLC6A3—Monoamine Transport—IL1B—Graves' disease	1.71e-05	0.00774	CbGpPWpGaD
Desipramine—SLC22A1—Transmission across Chemical Synapses—GABRA3—Graves' disease	1.7e-05	0.00772	CbGpPWpGaD
Desipramine—SLC6A4—Monoamine Transport—TNF—Graves' disease	1.63e-05	0.00737	CbGpPWpGaD
Desipramine—SLC22A4—Transmembrane transport of small molecules—GABRA3—Graves' disease	1.59e-05	0.00721	CbGpPWpGaD
Desipramine—SLC6A3—Neuronal System—GABRA3—Graves' disease	1.54e-05	0.00697	CbGpPWpGaD
Desipramine—SLC22A2—Neuronal System—GABRA3—Graves' disease	1.4e-05	0.00635	CbGpPWpGaD
Desipramine—SLC6A2—Monoamine Transport—TNF—Graves' disease	1.4e-05	0.00634	CbGpPWpGaD
Desipramine—SMPD1—Metabolism—GC—Graves' disease	1.4e-05	0.00633	CbGpPWpGaD
Desipramine—SLC22A1—Neuronal System—GABRA3—Graves' disease	1.31e-05	0.00592	CbGpPWpGaD
Desipramine—SLC6A3—Monoamine Transport—TNF—Graves' disease	1.24e-05	0.00562	CbGpPWpGaD
Desipramine—SLC22A3—Transmembrane transport of small molecules—GABRA3—Graves' disease	1.2e-05	0.00544	CbGpPWpGaD
Desipramine—SLC22A5—Transmembrane transport of small molecules—GABRA3—Graves' disease	1.2e-05	0.00542	CbGpPWpGaD
Desipramine—CHRM4—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	1.11e-05	0.00501	CbGpPWpGaD
Desipramine—CHRM5—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	1.06e-05	0.0048	CbGpPWpGaD
Desipramine—SMPD1—Metabolism—B3GNT2—Graves' disease	1.06e-05	0.0048	CbGpPWpGaD
Desipramine—ABCB1—Allograft Rejection—HLA-E—Graves' disease	1.05e-05	0.00475	CbGpPWpGaD
Desipramine—ABCB1—Allograft Rejection—CD40—Graves' disease	1.03e-05	0.00465	CbGpPWpGaD
Desipramine—ABCB1—Allograft Rejection—CTLA4—Graves' disease	1.01e-05	0.00458	CbGpPWpGaD
Desipramine—SLC6A2—Transmembrane transport of small molecules—GABRA3—Graves' disease	9.34e-06	0.00423	CbGpPWpGaD
Desipramine—ADRB1—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	9.07e-06	0.00411	CbGpPWpGaD
Desipramine—CHRM4—G alpha (i) signalling events—CXCL10—Graves' disease	8.98e-06	0.00407	CbGpPWpGaD
Desipramine—ADRB2—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	8.87e-06	0.00402	CbGpPWpGaD
Desipramine—SLC6A4—Circadian rythm related genes—FAS—Graves' disease	8.81e-06	0.00399	CbGpPWpGaD
Desipramine—HTR1A—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	8.67e-06	0.00393	CbGpPWpGaD
Desipramine—HTR2C—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	8.63e-06	0.00391	CbGpPWpGaD
Desipramine—CHRM4—GPCR ligand binding—TSHR—Graves' disease	8.42e-06	0.00381	CbGpPWpGaD
Desipramine—ABCB1—Allograft Rejection—HLA-DQB1—Graves' disease	8.32e-06	0.00377	CbGpPWpGaD
Desipramine—SLC6A3—Transmembrane transport of small molecules—GABRA3—Graves' disease	8.28e-06	0.00375	CbGpPWpGaD
Desipramine—CHRM5—GPCR ligand binding—TSHR—Graves' disease	8.06e-06	0.00365	CbGpPWpGaD
Desipramine—DRD2—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	7.62e-06	0.00345	CbGpPWpGaD
Desipramine—SLC22A2—Transmembrane transport of small molecules—GABRA3—Graves' disease	7.53e-06	0.00341	CbGpPWpGaD
Desipramine—HTR2A—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	7.49e-06	0.0034	CbGpPWpGaD
Desipramine—HRH1—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	7.48e-06	0.00339	CbGpPWpGaD
Desipramine—ABCB1—Allograft Rejection—HLA-B—Graves' disease	7.48e-06	0.00339	CbGpPWpGaD
Desipramine—CHRM1—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	7.45e-06	0.00338	CbGpPWpGaD
Desipramine—CHRM3—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	7.43e-06	0.00337	CbGpPWpGaD
Desipramine—CHRM2—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	7.36e-06	0.00333	CbGpPWpGaD
Desipramine—ABCB1—Allograft Rejection—FASLG—Graves' disease	7.31e-06	0.00331	CbGpPWpGaD
Desipramine—CHRM4—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	7.14e-06	0.00324	CbGpPWpGaD
Desipramine—HTR1A—G alpha (i) signalling events—CXCL10—Graves' disease	7.05e-06	0.00319	CbGpPWpGaD
Desipramine—ABCB1—Allograft Rejection—FAS—Graves' disease	7.05e-06	0.00319	CbGpPWpGaD
Desipramine—SLC22A1—Transmembrane transport of small molecules—GABRA3—Graves' disease	7.02e-06	0.00318	CbGpPWpGaD
Desipramine—ABCB1—Allograft Rejection—IL2RA—Graves' disease	7e-06	0.00317	CbGpPWpGaD
Desipramine—ABCB1—Allograft Rejection—HLA-A—Graves' disease	6.93e-06	0.00314	CbGpPWpGaD
Desipramine—ADRB1—GPCR ligand binding—TSHR—Graves' disease	6.91e-06	0.00313	CbGpPWpGaD
Desipramine—CHRM5—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	6.84e-06	0.0031	CbGpPWpGaD
Desipramine—ADRB2—GPCR ligand binding—TSHR—Graves' disease	6.76e-06	0.00306	CbGpPWpGaD
Desipramine—HTR1A—GPCR ligand binding—TSHR—Graves' disease	6.61e-06	0.00299	CbGpPWpGaD
Desipramine—HTR2C—GPCR ligand binding—TSHR—Graves' disease	6.57e-06	0.00298	CbGpPWpGaD
Desipramine—ABCB1—Allograft Rejection—HLA-DRB1—Graves' disease	6.33e-06	0.00287	CbGpPWpGaD
Desipramine—SLC6A4—SIDS Susceptibility Pathways—IL1B—Graves' disease	6.32e-06	0.00286	CbGpPWpGaD
Desipramine—DRD2—G alpha (i) signalling events—CXCL10—Graves' disease	6.19e-06	0.0028	CbGpPWpGaD
Desipramine—SLC22A3—Metabolism—GC—Graves' disease	6.05e-06	0.00274	CbGpPWpGaD
Desipramine—CHRM2—G alpha (i) signalling events—CXCL10—Graves' disease	5.98e-06	0.00271	CbGpPWpGaD
Desipramine—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	5.86e-06	0.00266	CbGpPWpGaD
Desipramine—DRD2—GPCR ligand binding—TSHR—Graves' disease	5.8e-06	0.00263	CbGpPWpGaD
Desipramine—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	5.73e-06	0.0026	CbGpPWpGaD
Desipramine—CYP2C18—Metabolism—GC—Graves' disease	5.72e-06	0.00259	CbGpPWpGaD
Desipramine—HTR2A—GPCR ligand binding—TSHR—Graves' disease	5.71e-06	0.00259	CbGpPWpGaD
Desipramine—HRH1—GPCR ligand binding—TSHR—Graves' disease	5.69e-06	0.00258	CbGpPWpGaD
Desipramine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—Graves' disease	5.69e-06	0.00258	CbGpPWpGaD
Desipramine—CHRM1—GPCR ligand binding—TSHR—Graves' disease	5.68e-06	0.00257	CbGpPWpGaD
Desipramine—CHRM3—GPCR ligand binding—TSHR—Graves' disease	5.66e-06	0.00256	CbGpPWpGaD
Desipramine—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	5.61e-06	0.00254	CbGpPWpGaD
Desipramine—CHRM2—GPCR ligand binding—TSHR—Graves' disease	5.6e-06	0.00254	CbGpPWpGaD
Desipramine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	5.58e-06	0.00253	CbGpPWpGaD
Desipramine—CHRM4—GPCR ligand binding—CXCL10—Graves' disease	5.44e-06	0.00246	CbGpPWpGaD
Desipramine—DRD2—Circadian rythm related genes—FAS—Graves' disease	5.39e-06	0.00244	CbGpPWpGaD
Desipramine—CHRM1—Circadian rythm related genes—FAS—Graves' disease	5.28e-06	0.00239	CbGpPWpGaD
Desipramine—CHRM5—GPCR ligand binding—CXCL10—Graves' disease	5.21e-06	0.00236	CbGpPWpGaD
Desipramine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—Graves' disease	5.07e-06	0.0023	CbGpPWpGaD
Desipramine—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	4.92e-06	0.00223	CbGpPWpGaD
Desipramine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	4.84e-06	0.00219	CbGpPWpGaD
Desipramine—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	4.83e-06	0.00219	CbGpPWpGaD
Desipramine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	4.82e-06	0.00218	CbGpPWpGaD
Desipramine—CHRM3—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	4.8e-06	0.00218	CbGpPWpGaD
Desipramine—CYP2C19—Metabolism of lipids and lipoproteins—GC—Graves' disease	4.77e-06	0.00216	CbGpPWpGaD
Desipramine—CHRM4—GPCR downstream signaling—TSHR—Graves' disease	4.76e-06	0.00216	CbGpPWpGaD
Desipramine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	4.75e-06	0.00215	CbGpPWpGaD
Desipramine—ABCB1—Allograft Rejection—IFNG—Graves' disease	4.62e-06	0.00209	CbGpPWpGaD
Desipramine—SLC22A3—Metabolism—B3GNT2—Graves' disease	4.58e-06	0.00208	CbGpPWpGaD
Desipramine—SLC6A4—SIDS Susceptibility Pathways—TNF—Graves' disease	4.58e-06	0.00208	CbGpPWpGaD
Desipramine—CHRM5—GPCR downstream signaling—TSHR—Graves' disease	4.56e-06	0.00206	CbGpPWpGaD
Desipramine—ADRB1—GPCR ligand binding—CXCL10—Graves' disease	4.46e-06	0.00202	CbGpPWpGaD
Desipramine—HTR1A—SIDS Susceptibility Pathways—IL1B—Graves' disease	4.4e-06	0.00199	CbGpPWpGaD
Desipramine—ADRB2—GPCR ligand binding—CXCL10—Graves' disease	4.37e-06	0.00198	CbGpPWpGaD
Desipramine—CYP2C18—Metabolism—B3GNT2—Graves' disease	4.33e-06	0.00196	CbGpPWpGaD
Desipramine—CHRM4—Signaling by GPCR—TSHR—Graves' disease	4.32e-06	0.00196	CbGpPWpGaD
Desipramine—HTR1A—GPCR ligand binding—CXCL10—Graves' disease	4.27e-06	0.00193	CbGpPWpGaD
Desipramine—HTR2C—GPCR ligand binding—CXCL10—Graves' disease	4.25e-06	0.00192	CbGpPWpGaD
Desipramine—CHRM5—Signaling by GPCR—TSHR—Graves' disease	4.14e-06	0.00187	CbGpPWpGaD
Desipramine—ABCB1—Allograft Rejection—IL1B—Graves' disease	4.12e-06	0.00187	CbGpPWpGaD
Desipramine—ABCB1—Transmembrane transport of small molecules—GABRA3—Graves' disease	4.11e-06	0.00186	CbGpPWpGaD
Desipramine—ADRB1—GPCR downstream signaling—TSHR—Graves' disease	3.9e-06	0.00177	CbGpPWpGaD
Desipramine—ADRB2—GPCR downstream signaling—TSHR—Graves' disease	3.82e-06	0.00173	CbGpPWpGaD
Desipramine—HTR2A—SIDS Susceptibility Pathways—IL1B—Graves' disease	3.8e-06	0.00172	CbGpPWpGaD
Desipramine—SLC22A2—Metabolism—GC—Graves' disease	3.79e-06	0.00172	CbGpPWpGaD
Desipramine—DRD2—GPCR ligand binding—CXCL10—Graves' disease	3.75e-06	0.0017	CbGpPWpGaD
Desipramine—HTR1A—GPCR downstream signaling—TSHR—Graves' disease	3.73e-06	0.00169	CbGpPWpGaD
Desipramine—CHRM2—SIDS Susceptibility Pathways—IL1B—Graves' disease	3.73e-06	0.00169	CbGpPWpGaD
Desipramine—CYP1A2—Metabolism of lipids and lipoproteins—GC—Graves' disease	3.72e-06	0.00168	CbGpPWpGaD
Desipramine—HTR2C—GPCR downstream signaling—TSHR—Graves' disease	3.71e-06	0.00168	CbGpPWpGaD
Desipramine—HTR2A—GPCR ligand binding—CXCL10—Graves' disease	3.69e-06	0.00167	CbGpPWpGaD
Desipramine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—Graves' disease	3.68e-06	0.00167	CbGpPWpGaD
Desipramine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—Graves' disease	3.68e-06	0.00167	CbGpPWpGaD
Desipramine—HRH1—GPCR ligand binding—CXCL10—Graves' disease	3.68e-06	0.00167	CbGpPWpGaD
Desipramine—CHRM1—GPCR ligand binding—CXCL10—Graves' disease	3.67e-06	0.00166	CbGpPWpGaD
Desipramine—CHRM3—GPCR ligand binding—CXCL10—Graves' disease	3.66e-06	0.00166	CbGpPWpGaD
Desipramine—CHRM2—GPCR ligand binding—CXCL10—Graves' disease	3.62e-06	0.00164	CbGpPWpGaD
Desipramine—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—Graves' disease	3.61e-06	0.00163	CbGpPWpGaD
Desipramine—ADRB1—Signaling by GPCR—TSHR—Graves' disease	3.54e-06	0.00161	CbGpPWpGaD
Desipramine—SLC22A1—Metabolism—GC—Graves' disease	3.54e-06	0.0016	CbGpPWpGaD
Desipramine—CYP2A6—Metabolism—GC—Graves' disease	3.48e-06	0.00158	CbGpPWpGaD
Desipramine—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—Graves' disease	3.48e-06	0.00158	CbGpPWpGaD
Desipramine—ADRB2—Signaling by GPCR—TSHR—Graves' disease	3.47e-06	0.00157	CbGpPWpGaD
Desipramine—HTR1A—Signaling by GPCR—TSHR—Graves' disease	3.39e-06	0.00154	CbGpPWpGaD
Desipramine—HTR2C—Signaling by GPCR—TSHR—Graves' disease	3.37e-06	0.00153	CbGpPWpGaD
Desipramine—DRD2—GPCR downstream signaling—TSHR—Graves' disease	3.28e-06	0.00149	CbGpPWpGaD
Desipramine—CHRM3—Metabolism—GC—Graves' disease	3.27e-06	0.00148	CbGpPWpGaD
Desipramine—HTR2A—GPCR downstream signaling—TSHR—Graves' disease	3.22e-06	0.00146	CbGpPWpGaD
Desipramine—HRH1—GPCR downstream signaling—TSHR—Graves' disease	3.22e-06	0.00146	CbGpPWpGaD
Desipramine—CHRM1—GPCR downstream signaling—TSHR—Graves' disease	3.21e-06	0.00145	CbGpPWpGaD
Desipramine—CHRM3—GPCR downstream signaling—TSHR—Graves' disease	3.2e-06	0.00145	CbGpPWpGaD
Desipramine—HTR1A—SIDS Susceptibility Pathways—TNF—Graves' disease	3.19e-06	0.00145	CbGpPWpGaD
Desipramine—CHRM2—GPCR downstream signaling—TSHR—Graves' disease	3.17e-06	0.00143	CbGpPWpGaD
Desipramine—CHRM4—GPCR downstream signaling—CXCL10—Graves' disease	3.07e-06	0.00139	CbGpPWpGaD
Desipramine—ABCB1—Allograft Rejection—TNF—Graves' disease	2.99e-06	0.00136	CbGpPWpGaD
Desipramine—DRD2—Signaling by GPCR—TSHR—Graves' disease	2.98e-06	0.00135	CbGpPWpGaD
Desipramine—CHRM5—GPCR downstream signaling—CXCL10—Graves' disease	2.94e-06	0.00133	CbGpPWpGaD
Desipramine—HTR2A—Signaling by GPCR—TSHR—Graves' disease	2.93e-06	0.00133	CbGpPWpGaD
Desipramine—HRH1—Signaling by GPCR—TSHR—Graves' disease	2.92e-06	0.00132	CbGpPWpGaD
Desipramine—CHRM1—Signaling by GPCR—TSHR—Graves' disease	2.91e-06	0.00132	CbGpPWpGaD
Desipramine—CHRM3—Signaling by GPCR—TSHR—Graves' disease	2.9e-06	0.00132	CbGpPWpGaD
Desipramine—CHRM2—Signaling by GPCR—TSHR—Graves' disease	2.88e-06	0.0013	CbGpPWpGaD
Desipramine—SLC22A2—Metabolism—B3GNT2—Graves' disease	2.88e-06	0.0013	CbGpPWpGaD
Desipramine—CYP2B6—Metabolism—GC—Graves' disease	2.81e-06	0.00127	CbGpPWpGaD
Desipramine—CHRM4—Signaling by GPCR—CXCL10—Graves' disease	2.79e-06	0.00126	CbGpPWpGaD
Desipramine—HTR2A—SIDS Susceptibility Pathways—TNF—Graves' disease	2.76e-06	0.00125	CbGpPWpGaD
Desipramine—CYP2E1—Metabolism—GC—Graves' disease	2.75e-06	0.00125	CbGpPWpGaD
Desipramine—CHRM2—SIDS Susceptibility Pathways—TNF—Graves' disease	2.71e-06	0.00123	CbGpPWpGaD
Desipramine—SLC22A1—Metabolism—B3GNT2—Graves' disease	2.68e-06	0.00121	CbGpPWpGaD
Desipramine—CHRM5—Signaling by GPCR—CXCL10—Graves' disease	2.67e-06	0.00121	CbGpPWpGaD
Desipramine—CYP2A6—Metabolism—B3GNT2—Graves' disease	2.64e-06	0.0012	CbGpPWpGaD
Desipramine—CHRM4—Signaling Pathways—TSHR—Graves' disease	2.55e-06	0.00116	CbGpPWpGaD
Desipramine—ADRB1—GPCR downstream signaling—CXCL10—Graves' disease	2.52e-06	0.00114	CbGpPWpGaD
Desipramine—CHRM3—Metabolism—B3GNT2—Graves' disease	2.48e-06	0.00112	CbGpPWpGaD
Desipramine—ADRB2—GPCR downstream signaling—CXCL10—Graves' disease	2.47e-06	0.00112	CbGpPWpGaD
Desipramine—CHRM5—Signaling Pathways—TSHR—Graves' disease	2.44e-06	0.00111	CbGpPWpGaD
Desipramine—HTR1A—GPCR downstream signaling—CXCL10—Graves' disease	2.41e-06	0.00109	CbGpPWpGaD
Desipramine—HTR2C—GPCR downstream signaling—CXCL10—Graves' disease	2.4e-06	0.00109	CbGpPWpGaD
Desipramine—CHRM4—GPCR downstream signaling—IL2RA—Graves' disease	2.35e-06	0.00106	CbGpPWpGaD
Desipramine—ADRB1—Signaling by GPCR—CXCL10—Graves' disease	2.29e-06	0.00104	CbGpPWpGaD
Desipramine—CHRM5—GPCR downstream signaling—IL2RA—Graves' disease	2.25e-06	0.00102	CbGpPWpGaD
Desipramine—ADRB2—Signaling by GPCR—CXCL10—Graves' disease	2.24e-06	0.00102	CbGpPWpGaD
Desipramine—HTR1A—Signaling by GPCR—CXCL10—Graves' disease	2.19e-06	0.000993	CbGpPWpGaD
Desipramine—HTR2C—Signaling by GPCR—CXCL10—Graves' disease	2.18e-06	0.000987	CbGpPWpGaD
Desipramine—CHRM4—Signaling by GPCR—IL2RA—Graves' disease	2.13e-06	0.000967	CbGpPWpGaD
Desipramine—CYP2B6—Metabolism—B3GNT2—Graves' disease	2.13e-06	0.000965	CbGpPWpGaD
Desipramine—CYP2C19—Metabolism—GC—Graves' disease	2.12e-06	0.000962	CbGpPWpGaD
Desipramine—DRD2—GPCR downstream signaling—CXCL10—Graves' disease	2.12e-06	0.00096	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—TSHR—Graves' disease	2.09e-06	0.000949	CbGpPWpGaD
Desipramine—CYP2E1—Metabolism—B3GNT2—Graves' disease	2.09e-06	0.000945	CbGpPWpGaD
Desipramine—HTR2A—GPCR downstream signaling—CXCL10—Graves' disease	2.08e-06	0.000944	CbGpPWpGaD
Desipramine—HRH1—GPCR downstream signaling—CXCL10—Graves' disease	2.08e-06	0.000942	CbGpPWpGaD
Desipramine—CHRM1—GPCR downstream signaling—CXCL10—Graves' disease	2.07e-06	0.000939	CbGpPWpGaD
Desipramine—ABCB1—Metabolism—GC—Graves' disease	2.07e-06	0.000939	CbGpPWpGaD
Desipramine—CHRM3—GPCR downstream signaling—CXCL10—Graves' disease	2.07e-06	0.000936	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—TSHR—Graves' disease	2.05e-06	0.000928	CbGpPWpGaD
Desipramine—CHRM2—GPCR downstream signaling—CXCL10—Graves' disease	2.05e-06	0.000927	CbGpPWpGaD
Desipramine—CHRM5—Signaling by GPCR—IL2RA—Graves' disease	2.04e-06	0.000926	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—TSHR—Graves' disease	2e-06	0.000907	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—TSHR—Graves' disease	1.99e-06	0.000903	CbGpPWpGaD
Desipramine—CYP2D6—Metabolism—GC—Graves' disease	1.95e-06	0.000885	CbGpPWpGaD
Desipramine—ADRB1—GPCR downstream signaling—IL2RA—Graves' disease	1.93e-06	0.000873	CbGpPWpGaD
Desipramine—DRD2—Signaling by GPCR—CXCL10—Graves' disease	1.92e-06	0.000871	CbGpPWpGaD
Desipramine—HTR2A—Signaling by GPCR—CXCL10—Graves' disease	1.89e-06	0.000857	CbGpPWpGaD
Desipramine—HRH1—Signaling by GPCR—CXCL10—Graves' disease	1.89e-06	0.000856	CbGpPWpGaD
Desipramine—ADRB2—GPCR downstream signaling—IL2RA—Graves' disease	1.89e-06	0.000854	CbGpPWpGaD
Desipramine—CHRM1—Signaling by GPCR—CXCL10—Graves' disease	1.88e-06	0.000853	CbGpPWpGaD
Desipramine—CHRM3—Signaling by GPCR—CXCL10—Graves' disease	1.88e-06	0.00085	CbGpPWpGaD
Desipramine—CHRM2—Signaling by GPCR—CXCL10—Graves' disease	1.86e-06	0.000842	CbGpPWpGaD
Desipramine—HTR1A—GPCR downstream signaling—IL2RA—Graves' disease	1.84e-06	0.000835	CbGpPWpGaD
Desipramine—HTR2C—GPCR downstream signaling—IL2RA—Graves' disease	1.83e-06	0.000831	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—TSHR—Graves' disease	1.76e-06	0.000797	CbGpPWpGaD
Desipramine—ADRB1—Signaling by GPCR—IL2RA—Graves' disease	1.75e-06	0.000793	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—TSHR—Graves' disease	1.73e-06	0.000784	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—TSHR—Graves' disease	1.73e-06	0.000782	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—TSHR—Graves' disease	1.72e-06	0.00078	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—TSHR—Graves' disease	1.72e-06	0.000777	CbGpPWpGaD
Desipramine—ADRB2—Signaling by GPCR—IL2RA—Graves' disease	1.71e-06	0.000776	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—TSHR—Graves' disease	1.7e-06	0.00077	CbGpPWpGaD
Desipramine—HTR1A—Signaling by GPCR—IL2RA—Graves' disease	1.67e-06	0.000759	CbGpPWpGaD
Desipramine—HTR2C—Signaling by GPCR—IL2RA—Graves' disease	1.67e-06	0.000755	CbGpPWpGaD
Desipramine—CYP1A2—Metabolism—GC—Graves' disease	1.65e-06	0.00075	CbGpPWpGaD
Desipramine—CHRM4—Signaling Pathways—CXCL10—Graves' disease	1.65e-06	0.000747	CbGpPWpGaD
Desipramine—DRD2—GPCR downstream signaling—IL2RA—Graves' disease	1.62e-06	0.000733	CbGpPWpGaD
Desipramine—CYP2C19—Metabolism—B3GNT2—Graves' disease	1.61e-06	0.000729	CbGpPWpGaD
Desipramine—HTR2A—GPCR downstream signaling—IL2RA—Graves' disease	1.59e-06	0.000722	CbGpPWpGaD
Desipramine—HRH1—GPCR downstream signaling—IL2RA—Graves' disease	1.59e-06	0.00072	CbGpPWpGaD
Desipramine—CHRM1—GPCR downstream signaling—IL2RA—Graves' disease	1.58e-06	0.000718	CbGpPWpGaD
Desipramine—CHRM5—Signaling Pathways—CXCL10—Graves' disease	1.58e-06	0.000716	CbGpPWpGaD
Desipramine—CHRM3—GPCR downstream signaling—IL2RA—Graves' disease	1.58e-06	0.000716	CbGpPWpGaD
Desipramine—ABCB1—Metabolism—B3GNT2—Graves' disease	1.57e-06	0.000712	CbGpPWpGaD
Desipramine—CHRM2—GPCR downstream signaling—IL2RA—Graves' disease	1.56e-06	0.000709	CbGpPWpGaD
Desipramine—CYP2D6—Metabolism—B3GNT2—Graves' disease	1.48e-06	0.000671	CbGpPWpGaD
Desipramine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	1.48e-06	0.000669	CbGpPWpGaD
Desipramine—DRD2—Signaling by GPCR—IL2RA—Graves' disease	1.47e-06	0.000666	CbGpPWpGaD
Desipramine—HTR2A—Signaling by GPCR—IL2RA—Graves' disease	1.45e-06	0.000655	CbGpPWpGaD
Desipramine—HRH1—Signaling by GPCR—IL2RA—Graves' disease	1.44e-06	0.000654	CbGpPWpGaD
Desipramine—CHRM1—Signaling by GPCR—IL2RA—Graves' disease	1.44e-06	0.000652	CbGpPWpGaD
Desipramine—CHRM3—Signaling by GPCR—IL2RA—Graves' disease	1.43e-06	0.00065	CbGpPWpGaD
Desipramine—CHRM2—Signaling by GPCR—IL2RA—Graves' disease	1.42e-06	0.000643	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—CXCL10—Graves' disease	1.35e-06	0.000613	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—CXCL10—Graves' disease	1.32e-06	0.0006	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—CXCL10—Graves' disease	1.29e-06	0.000586	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—CXCL10—Graves' disease	1.29e-06	0.000583	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—GC—Graves' disease	1.28e-06	0.000579	CbGpPWpGaD
Desipramine—CHRM4—Signaling Pathways—IL2RA—Graves' disease	1.26e-06	0.000571	CbGpPWpGaD
Desipramine—CYP1A2—Metabolism—B3GNT2—Graves' disease	1.25e-06	0.000568	CbGpPWpGaD
Desipramine—CHRM5—Signaling Pathways—IL2RA—Graves' disease	1.21e-06	0.000547	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—CXCL10—Graves' disease	1.14e-06	0.000515	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—CXCL10—Graves' disease	1.12e-06	0.000507	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—CXCL10—Graves' disease	1.12e-06	0.000505	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—CXCL10—Graves' disease	1.11e-06	0.000504	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—CXCL10—Graves' disease	1.11e-06	0.000502	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—CXCL10—Graves' disease	1.1e-06	0.000497	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—IL2RA—Graves' disease	1.03e-06	0.000468	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—IL2RA—Graves' disease	1.01e-06	0.000458	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—IL2RA—Graves' disease	9.89e-07	0.000448	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—IL2RA—Graves' disease	9.84e-07	0.000446	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—B3GNT2—Graves' disease	9.68e-07	0.000438	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—IL2RA—Graves' disease	8.68e-07	0.000393	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—IL2RA—Graves' disease	8.54e-07	0.000387	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—IL2RA—Graves' disease	8.53e-07	0.000386	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—IL2RA—Graves' disease	8.5e-07	0.000385	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—IL2RA—Graves' disease	8.47e-07	0.000384	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—IL2RA—Graves' disease	8.39e-07	0.00038	CbGpPWpGaD
